Literature DB >> 11174351

An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major.

H I Karvounis1, T A Zaglavara, G E Parharidis, I G Nouskas, E P Hassapopoulou, K D Gemitzis, G E Louridas.   

Abstract

BACKGROUND: Cardiac complications are the major cause of death in patients with beta-thalassemia major. The purpose of this study was to assess the impact of long-term treatment with the angiotensin-converting enzyme inhibitor enalapril on left ventricular (LV) performance, with an emphasis on diastolic LV function because diastolic dysfunction has been found to be an early event in an asymptomatic thalassemic population with only mild impairment of LV systolic function.
METHODS: We used echocardiography to study the impact of treatment with oral enalapril on the evolution of standard M-mode and Doppler indices, along with a recently introduced Doppler index of combined systolic and diastolic LV performance.
RESULTS: Patients were found to have significantly increased LV end-diastolic dimensions (LVEDD), LV end-systolic dimensions (LVESD), and left atrial dimensions and decreased LV fractional shortening (LVFS) compared with controls. After treatment with enalapril, LVESD decreased from 3.58 +/- 0.3 cm to 3.23 +/- 0.4 cm (P <.01) and LVFS increased from 32.6% +/- 4.0% to 38.0% +/- 3.1% (P <.001). Patients at baseline were found to have a significantly higher E-wave velocity, E/A ratio, and Doppler index compared with controls. The E-wave deceleration time was significantly shorter compared with that of controls. After treatment with enalapril, the E/A ratio decreased from 2.10 +/- 0.42 to 1.50 +/- 0.30 (P <.05), E-wave deceleration time increased from 0.12 +/- 0.02 seconds to 0.15 +/- 0.03 seconds (P <.01), and the Doppler index decreased from 0.46 +/- 0.10 to 0.37 +/- 0.14 (P <.05).
CONCLUSIONS: Enalapril was well tolerated in asymptomatic or minimally symptomatic patients with LV dysfunction resulting from beta-thalassemia major. Echocardiographically we demonstrated significant improvement in LV systolic and diastolic function. Whether this translates to improved long-term prognosis and survival remains to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174351     DOI: 10.1067/mhj.2001.112090

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Ventriculo-vascular interactions in patients with beta thalassaemia major.

Authors:  Y F Cheung; S Y Ha; G C F Chan
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

2.  The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance.

Authors:  Ebru Aypar; Dursun Alehan; Tuncay Hazirolan; Fatma Gümrük
Journal:  Int J Cardiovasc Imaging       Date:  2010-02-02       Impact factor: 2.357

3.  Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia.

Authors:  Suchaya Silvilairat; Pimlak Charoenkwan; Suwit Saekho; Adisak Tantiworawit; Nipon Chattipakorn
Journal:  Ann Pediatr Cardiol       Date:  2021-05-03

4.  Dynamic dyssynchrony and impaired contractile reserve of the left ventricle in beta-thalassaemia major: an exercise echocardiographic study.

Authors:  Yiu-fai Cheung; Wei Yu; Shu-na Li; Wendy W M Lam; Yuen-chi Ho; Sophia J Wong; Godfrey C F Chan; Shau-yin Ha
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function.

Authors:  Benjaporn Chinprateep; Nithima Ratanasit; Yodying Kaolawanich; Khemajira Karaketklang; Pairash Saiviroonporn; Vip Viprakasit; Rungroj Krittayaphong
Journal:  BMC Cardiovasc Disord       Date:  2019-11-06       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.